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Assessment of functional status and quality of life
in claudication
Ryan J. Mays, PhD,a,e Ivan P. Casserly, MB, BCh,a Wendy M. Kohrt, PhD,b,e P. Michael Ho, MD, PhD,a
William R. Hiatt, MD,a Mark R. Nehler, MD,c and Judith G. Regensteiner, PhDa,d,e Aurora, Colo
Background: Treadmill walking is commonly used to evaluate walking impairment and efficacy of treatment for
intermittent claudication (IC) in clinical and research settings. Although this is an important measure, it does not provide
information about how patients perceive the effects of their treatments on more global measures of health-related quality
of life (HRQOL).
Methods: PubMed/Medline was searched to find publications about the most commonly used questionnaires to assess
functional status and/or general and disease-specific HRQOL in patients with peripheral artery disease (PAD) who
experience IC. Inclusion criteria for questionnaires were based on existence of a body of literature in symptomatic PAD.
Results: Six general questionnaires and seven disease-specific questionnaires are included, with details about the number
of domains covered and how each tool is scored. The Medical Outcomes Study Short Form 36-item questionnaire and
Walking Impairment Questionnaire are currently the most used general and disease-specific questionnaires at baseline
and after treatment for IC, respectively.
Conclusions: The use of tools that assess functional status and HRQOL has importance in both the clinical and research
areas to assess treatment efficacy from the patient’s perspective. Therefore, assessing HRQOL in addition to treadmill-
measured walking ability provides insight as to the effects of treatments on patient outcomes and may help guide therapy.
(J Vasc Surg 2011;53:1410-21.)
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IPeripheral artery disease (PAD) results from atheroscle-
rotic plaque in the major arteries of the lower extremities,
causing decreased blood flow in the legs during exertion.
Symptomatic PAD patients experience intermittent claudi-
cation (IC), which is characterized by cramping, fatigue
and/or aching in the calves, thighs, or buttocks, typically
brought on by walking and relieved by rest and which also
causes impairments in quality of life.1 Because of claudica-
tion pain, individuals with PAD often avoid physical activ-
ity, especially ambulation, thus leading to additional de-
clines in functional status and health-related quality of life
(HRQOL), defined as the patient’s perceived physical,
emotional, and social well-being and function.2-4 PAD
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1410atients with IC may be limited in performing certain
ctivities of daily living and may also feel that they are a
urden to themselves as well as their family.5
It is important to assess how an individual perceives his
r her own health because this information may be useful
or determining appropriate treatment strategy and subse-
uently providing positive outcomes.6 This review de-
cribes the impairments of functional status and HRQOL
xperienced by symptomatic PAD patients, as assessed by
oth general and PAD-specific questionnaires. The effects
f PAD treatment (eg, supervised and unsupervised exer-
ise, endovascular therapy, open-surgery procedures, med-
cations) on functional status and HRQOL for patients
ith IC and the potential usage and relevance of these
nstruments in clinical and research settings is also dis-
ussed.
PIDEMIOLOGY OF SYMPTOMATIC PAD
It has been estimated that 8 to 12 million adults have
AD in the U.S. and that approximately one-third experi-
nce IC.7,8 According to the Trans-Atlantic InterSocietal
onsensus II international guidelines, the prevalence of
ymptomatic PAD is approximately 2% to 7% in patients
ged 50 to 70 years.1 In addition to the high prevalence of
C, all persons with PAD have a significantly increased risk
f cardiovascular morbidity and mortality.9,10
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Volume 53, Number 5 Mays et al 1411OBJECTIVE MEASURES OF FUNCTIONAL
STATUS IN CLAUDICATION
Treadmill testing is an established means to objectively
determine walking ability in PAD patients and is highly
predictive of long-term morbidity and mortality out-
comes.11,12 Typically, time and/or distance to onset of
claudication and maximal time and/or distance walked
until test termination due to leg pain are considered gold
standard end points by which to assess walking ability for
patients with IC. Other validated, objective physical mea-
surements of functional status include the 6-minute walk
test and the Short Physical Performance Battery.13,14 These
functional performance measures are more strongly associ-
ated with physical activity levels during daily life than
treadmill walking and both are valid and reliable in objec-
tively assessing physical function for patients with IC.15-17
However, none of these tests address a patient’s perception
of his or her walking ability or HRQOL. In addition, other
important elements of health status, such as mental health,
emotional well-being, and social functioning, can be as-
sessed only by questionnaires.
FUNCTIONAL STATUS/HRQOL
QUESTIONNAIRES FOR SYMPTOMATIC PAD
Functional status can be defined “. . . as the level of
activities performed by an individual to realize needs of
daily living in many aspects of life, including physical,
psychological, social, spiritual, intellectual, and roles.”18
HRQOL can be defined as an individual’s multifaceted
perception of his or her overall health and well-being,
including the effect of illness, treatment, and other aspects
of his or her daily life.19,20 Questionnaire utilization has
been a part of research studies seeking to evaluate func-
tional status and HRQOL in cross-sectional evaluation or
at baseline and after treatment for claudication. However,
Table I. Original development and validation studies for g
or health-related quality of life in symptomatic peripheral a
Questionnaires First author (year)
SF-36 Ware6 (1992)
McHorney113 (1993)
SF-12 Ware28 (1996)
EuroQOL EuroQOL group31 (1990)
Brooks32 (1996)b
NHP Hunt43 (1980)
Hunt42 (1980)
WHOQOL-100 WHOQOL group114 (1994)
WHOQOL group115 (1994)
MHIQ Chambers116 (1976)
Sackett117 (1977)
Chambers118 (1984)
EuroQOL, European Quality of Life questionnaire; MHIQ, McMaster Hea
12-item questionnaire; SF-36, Short Form 36-item questionnaire; WHOQO
aIndicates worst to best.
bDescription for five dimension version.
cComposed of 24 “facets” within the six quality of life domains.
dScoring for each “facet” or domain.assessment of functional status and HRQOL in clinical qettings using valid and reliable questionnaires is important
n that appropriate questionnaires can assist health care
roviders in determining the level of impairment and se-
ecting appropriate care for patients with IC. Question-
aires are often compared with objective measures such as
readmill walking to establish validity. There is also practical
alue for using questionnaires from a clinical standpoint, in
hat treadmill tests are more expensive than questionnaires.
Typically, two types of questionnaires are used in pa-
ients with IC. Functional status questionnaires focus pri-
arily on the ability to complete physical activities and
elf-reported walking ability.21 Domains such as life satis-
action, morale, and happiness are assessed by broader
uality of life questionnaires that address overall well-being
nd function stemming from emotional and social aspects
f life.22 These types of questionnaires can be further
ivided into two main categories: general and disease-
pecific. General assessment tools are applicable to a wide
ange of patient populations, in contrast to disease-specific
uestionnaires. Tables I and II summarize the originating
nd/or validation studies for general and disease-specific
uestionnaires for PAD used in assessing functional status
nd HRQOL in symptomatic PAD patients.
General questionnaires. An important aspect of gen-
ral health questionnaires is that comparative analyses can
e performed in patient populations across disease states,
hus providing the ability to describe the relative severity
nd effect of the disease in question. A number of general
ealth questionnaires have been used to assess functional
tatus and HRQOL for PAD patients with IC. Table III
escribes functional status and/or HRQOL after exercise
raining for patients with IC. Table IV summarizes the
RQOL outcomes after vascular procedures for the other
ools described in this review. Table V describes the effect
f pharmacologic therapies on quality of life assessed by
al questionnaires used in assessing functional status and/
al disease patients
Domains/subscales Items Scoring rangea
8 36 0-100
8 12 0-100
5 5 0-1
7 45 100-0
6c 100 4-20d
3 59 0-1
dex Questionnaire; NHP, Nottingham Health Profile; SF-12, Short Form
, World Health Organization Quality of Life Assessment Instrument 100.ener
rteri
lth In
L-100uestionnaires for patients with IC.
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May 20111412 Mays et alShort Form 36-Item questionnaire. The Medical
Outcomes Study (MOS) Short Form (SF) questionnaires
were constructed in part to provide practical tools for
routine monitoring of patient outcomes in medical practice
as well as for research.23 The SF-36 provides a brief yet
comprehensive assessment of HRQOL.6 It measures eight
domains: physical, role and social functioning, mental
health, patient health perceptions, vitality, bodily pain, and
change in health. The SF-36, for which each individual
domain is transformed to a score of 0 to 100, with 100
Table II. Original development and validation studies for
status and/or health-related quality of life in symptomatic
Questionnaires First author (year)
WIQ Regensteiner66 (1990)
CLAU-S Finger87 (1995)
PAVK-86 Heidrich119 (1995)
VascuQOL Morgan96 (2001)
PAQ Morgan82 (2001)
SIPIC Gilson
103 (1975)
Bergner104 (1976)
Arfvidsson105 (1993)b
ICQ Chong107 (2002)
CLAU-S, Claudication Scale; ICQ, Intermittent Claudication Questionnair
Disease 86-item questionnaire; SIPIC, Sickness Impact Profile – Intermitten
Impairment Questionnaire.
aIndicates worst to best.
bDescribes the SIPIC version of the questionnaire.
Table III. Functional status and/or health-related quality
claudication
First author (year)
Sample
sizea Intervala Questionnai
Regensteiner76 (1996)b 21 24 weeks WIQ
Patterson120 (1997) 38 24 weeks SF-36
Regensteiner79 (1997)b 20 12 weeks WIQ
Wullink77 (2001) 24 24 weeks WIQ
Nicolai78 (2009) 91 12 weeks SF-36
EuroQOL
WIQ
Nicolai75 (2010) 252 1 year SF-36
WIQ
EuroQOL, European Quality of Life questionnaire; SF-36, Short Form 36-i
aIndicates final sample size for claudicant patients and final outcome assessm
bAlso used SF-20, which was not discussed in this review.
cUsed additional coaching in the home-based setting but did not directly su
dProvided an accelerometer to patients for additional feedback.being the best possible score (results can also be separated dnto physical and mental component summary scores), has
een extensively validated for assessing HRQOL in symp-
omatic PAD patients. It is one of the most commonly used
eneral health questionnaires for this purpose in addition to
ts broad use across many disease states.24 PAD patients
ith IC report lower scores in physical functioning, physi-
al limitations, and bodily pain compared with healthy
ontrols and the general population.25,26
TheMOS questionnaires have been used extensively to
ssess the results of bypass surgery, endovascular proce-
se-specific questionnaires used in assessing functional
heral arterial disease patients
ains/subscales Items Scoring rangea
4 22 0-100
5 47 0-100
7 86 4-1
5 25 1-7
7 20 0-100
6b 12b 12-0b
1 16 0-100
, Peripheral Artery Questionnaire; PAVK-86, Peripheral Artery Occlusive
dication; VascuQOL, Vascular Quality of Life questionnaire;WIQ,Walking
fe after exercise training for patients with intermittent
Type of training Outcome
Supervised exercise;
strength training;
nonexercise
Supervised group improved WIQ
scores
Supervised exercise;
home-based exercise
Improvement in physical
function, pain and physical
component scores for both
groups
Supervised exercise;
unsupervised exercise
Supervised group improved WIQ
walking distance and speed
scores
Unsupervised exercisec Pain, distance, speed, and stair
climbing domains improved
but not significantly
Supervised exercise All WIQ domains improved;
largest effect for SF-36 was
pain and physical functioning;
EuroQOL index improved
Supervised exercise;
supervised exercise;d
unsupervised exercise
Physical summary score of SF-36
improved, no improvement in
mental summary score; total
WIQ scores improved
uestionnaire; WIQ, Walking Impairment Questionnaire.
me point.
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Volume 53, Number 5 Mays et al 1413logic treatment. Recently, Mazari et al27 examined the
HRQOL of symptomatic PAD patients using the SF-36
before and 12 weeks after endovascular therapy, supervised
exercise, and a combination of the two groups. Endovas-
cular therapy and exercise training each independently re-
sulted in improvements in the domains of physical func-
tioning and physical role limitations. However, the
combined interventions demonstrated the greatest impact
on perceived quality of life, as six of the eight total domains
of the SF-36 significantly improved. A number of studies
have compared HRQOL across the different treatment
options. Table VI summarizes the functional status and/or
Table IV. Functional status and/or health-related quality
endovascular therapy and/or bypass surgery
First author (year)
Sample
sizea Intervala Questionnaires
Regensteiner80 (1993) 14 12 weeks WIQ
Cook33 (1996) 29 6 weeks EuroQOL
Cook34 (1997) 24 1 year EuroQOL
Chetter (1998)35 117 1 year SF-36
EuroQOL
Bosch36 (1999)b 101 2 years SF-36
EuroQOL
Bosch37 (2000)b 72 1 year SF-36
EuroQOL
Klevsgard54 (2000) 67 24 weeks NHP
Klevsgard52 (2001) 84 1 year NHP
Klevsgard53 (2002) 40 4 weeks SF-36
NHP
Wann-Hansson55 (2004) 38 1 year SF-36
NHP
Spertus82 (2004) 35 6 weeks SF-36
WIQ
PAQ
Wann-Hansson49 (2005) 51 4 years NHP
Murphy81 (2005) 35 1 year SF-36
WIQ
Safley30 (2007) 258 1 year SF-12
EuroQOL
PAQ
Egberg38 (2010) 41 1 year EuroQOL
CLAU-S
CLAU-S, Claudication Scale; EuroQOL, European Quality of Life question
SF-12, Short Form 12-item questionnaire; SF-36, Short Form 36-item ques
aIndicates final sample size for claudicants and final outcome assessment tim
bAlso used health utilities index, time tradeoff, standard gamble and rating
cAfter successful revascularization.HRQOL questionnaires nested within individual studies mfter multiple interventions. Briefly, the most effective in-
erventions for improving patient’s quality of life included
ombinations of treatments.
SF 12-item questionnaire. The SF-12 extracts select
tems from all eight domains of the SF-36 and includes the
ame physical and mental component summary scores.28 It
as designed to be a simpler version of the SF-36, scored in
he same way as the SF-36. Using the SF-12, Smolderen et
l29 assessed baseline HRQOL of symptomatic PAD pa-
ients compared with chronic heart failure patients. Results
ndicated that the physical domains were affected to a
reater extent in PAD patients, whereas the mental do-
fe in symptomatic peripheral arterial disease patients after
ascular procedure Outcomes
ass surgery; All domains improved
dovascular therapy Both EuroQOL total and VAS scores
improved
dovascular therapy EuroQOL total and VAS scores improved,
except VAS perceived health state score
dovascular therapy Improved most domains, depending on
site/severity of disease; no effect on
psychological domains
dovascular therapy Greatest effect in SF-36 physical
functioning, physical role limitations
and bodily pain; EuroQOL improved
dovascular therapy Improvement in all SF-36 domains;
increase in EuroQOL mobility, usual
activities, pain/discomfort domains
dovascular therapy;
ypass surgery
Improved all domains except sex life
dovascular therapy;
ypass surgery
Improvements in Part I scores except
social isolation for successful
endovascular therapy; improved Part II
scores of pain, emotional reactions
dovascular therapy;
ypass surgery
cNo improvement for SF-36 mental health
or social functioning; no improvement
for NHP social isolation, which was a
zero value pre- and post
dovascular therapy;
ypass surgery
Significant improvements in SF-36 bodily
pain and physical functioning; no
improvements in NHP scores
dovascular therapy Improvements in SF-36 physical, social
domains and all WIQ and PAQ domains
dovascular therapy;
ypass surgery
Total NHP score improved compared to
baseline
dovascular therapy SF-36 physical functioning, role physical,
bodily pain, & vitality improved; all
WIQ domains improved
dovascular therapy Improvements in SF-12 and EuroQOL
physical scores; all PAQ scores improved
except treatment satisfaction
dovascular therapy EuroQOL total index score and all 5
dimensions of CLAU-S improved
NHP, Nottingham Health Profile; PAQ, Peripheral Artery Questionnaire;
ire; VAS, visual analogue scale; WIQ, Walking Impairment Questionnaire.
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May 20111414 Mays et altients. Safley et al30 established that the physical compo-
nent summary scores improved after endovascular therapy
in a cohort of mostly PAD patients with claudication and a
small number of patients with critical limb ischemia (CLI),
similar to studies using other versions of the MOS Short
Form. More research is needed to determine the effect of
other treatment methods on SF-12 scores for symptomatic
PAD patients. However, because it is a relatively short
questionnaire compared with other general health ques-
tionnaires, it may be practical for use in clinical settings.
European Quality of Life Questionnaire. The Eu-
ropean Quality of Life Questionnaire (EuroQOL) is a
combined functional status and HRQOL instrument
that assesses five domains, including mobility, self-care,
usual activities, pain/discomfort, and anxiety/depres-
sion.31,32 The questionnaire administrator scores the
EuroQOL by applying a single summary index from 0 to
1, with 0 representing the worst health state and 1
representing perfect health. A second, separate part of
the EuroQOL is the visual analogue scale (VAS), which
Table V. Effects of pharmacologic therapy on functional s
peripheral arterial disease patients
First author (year)
Sample
sizea Intervala Questionnaires
Creutzig93 (1997) 93 12 weeks SF-36
PAVK-86
PG
Money121 (1998) 212 16 weeks SF-36
WIQ
Cil
p
Beebe122 (1999) 413 24 weeks SF-36
WIQ
Cil
p
Hiatt123 (2001) 155 24 weeks SF-36
WIQ
Pro
(
Strandness86 (2002) 286 24 weeks SF-36
WIQ
Cil
p
Hiatt83 (2004) 300 24 weeks SF-36
WIQ
bA
4
Hiatt84 (2004) 328 1 year WIQ Av
7
Creager124 (2008) 214 24 weeks SF-36
WIQ
Ilo
1
Pen
p
PAVK-86, Peripheral Artery Occlusive Disease 86-item questionnaire; PG
Impairment Questionnaire.
aIndicates final sample size of claudicants and final outcome assessment tim
b5-HT2A serotonin receptor antagonist.asks patients to draw a line on a 0 to 100 “thermometer” scale, rating their health from worst imaginable health to
est imaginable health (transformed to the summary
ndex of 0 to 1 as well).
The EuroQOL has been used to examine the effects of
ndovascular therapy for PAD patients. Generally, endo-
ascular therapy improvedmany of the domains included in
he questionnaire.30,33-38 Several studies have also com-
ared treatments, including supervised exercise, endovas-
ular therapy, and optimal medical therapy.39-41 Spronk et
l41 found that endovascular therapy and supervised exer-
ise training both resulted in improved EuroQOL scores 6
nd 12 months after treatment. There were no differences
etween the treatment groups, suggesting that supervised
xercise and endovascular therapy have similar value for
mproving HRQOL for up to 1 year. The EuroQOL is a
rief, easy-to-use questionnaire that may have practical
alue for use in clinical settings.
NottinghamHealth Profile. The Nottingham Health
rofile (NHP) evaluates functional status andHRQOL and
as been used for patients with IC, primarily in European
and/or health-related quality of life in symptomatic
Medication Outcomes
0 g) Greatest enhancements for SF-36
domains physical function, pain and
physical role limitations; pain and
functional status most improved
PAVK-86 domains
ol (100 mg);
o
Improvement in SF-36 physical domains
and WIQ walking speed and measures
of walking difficulty compared to
placebo
ol (100 mg; 50 mg);
o
Physical health domains of SF-36
improved for both cilostazol groups
compared to placebo; WIQ walking
speed and distance better in both
cilostazol groups
yl-L-carnitine
); placebo
Propionyl-L-carnitine improved SF-36
domains of physical role functioning,
bodily pain and health transition
scores; also improved WIQ distance
and speed scores
ol (100 mg; 50 mg);
o
Time point analysis indicated
improvements in all physical domains
for cilostazol vs placebo groups
5 (10 mg; 20 mg;
); placebo
No differences among SF-36 and WIQ
scores between groups
e (50 mg; 250 mg;
g); placebo
Greatest enhancement in WIQ distance
score seen in group receiving 50-mg
dosage
(50 g; 100 g;
g)
ylline (400 mg);
o
No differences between groups for SF-
36; stair-climbing only WIQ domain
to improve
staglandin E1; SF-36, Short Form 36-item questionnaire; WIQ, Walking
t.tatus
E1 (5
ostaz
laceb
ostaz
laceb
pion
6 mg
ostaz
laceb
T-101
0 mg
asimib
50-m
prost
50 
toxif
laceb
E1, protudies.22,42,43 TheNHP contains two sections: Section I is
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Volume 53, Number 5 Mays et al 1415composed of 38 yes/no response items and six domains
that include sleep, energy, emotional reactions, social iso-
lation, physical mobility, and pain. Section II examines
patient difficulties with daily activities by using seven gen-
eral yes/no questions. These include the areas of employ-
ment, housework, family relationships, social life, sex life,
hobbies, and holidays. Higher scores indicate greater
health problems, on a scale of 0 to 100. Studies have
examined HRQOL using the NHP for claudicant patients
compared with controls or CLI patients.44-46 Khaira et al46
demonstrated that symptomatic PAD patients have greater
impairments in the NHP domains of energy, pain, emo-
tional reactions, sleep, and physical mobility compared with
age and sex-matched controls. Klevsgard et al44 deter-
mined that the areas of pain, sleep, and physical mobility are
significantly better for PAD patients with IC compared
with CLI patients, with no differences in energy, emotional
reaction, or social isolation.
Other studies have yielded mixed results when examin-
ing the change in HRQOL after vascular intervention for
Table VI. Studies employing general and disease-specific
related quality of life in symptomatic peripheral arterial dise
First author (year)
Sample
sizea Intervala Questionnaires
Currie125 (1995) 186 12 weeks SF-36
Whyman51 (1996) 62 24 weeks NHP
Whyman50 (1997) 62 2 years NHP
De Vries39 (2005) 348 24 weeks SF-36
EuroQOL
VascuQOL
Kakkos109 (2005)b 26 24 weeks SF-36
WIQ
ICQ
Imfeld95 (2006) 55 24 weeks SF-36
WIQ
PAVK-86
Mehta40 (2006) 70 24 weeks SF-36
EuroQOL
VascuQOL
SIPIC
CLAU-S
Nylaende91 (2007) 48 2 years SF-36
EuroQOLd
CLAU-S
Spronk41 (2008) 150 1 year SF-36
EuroQOL
Mazari27 (2010) 157 12 weeks SF-36
VascuQOL
CLAU-S,Claudication Scale; EuroQOL, European Quality of Life questionn
compression; NHP, Nottingham Health Profile; PAVK-86, Peripheral
questionnaire; SIPIC, Sickness Impact Profile – Intermittent Claudication;
Questionnaire.
aIndicates final sample size for claudicants and final outcome assessment tim
bSix month active treatment time point described.
cClopidgrel, 75-mg once daily.
dUsed the visual analogue scale.
ePatients completed a circuit exercise program.IC.47-55 Koivunen and Lukkarinen47 determined that re- rascularization improved the domains of emotional reac-
ions, energy, and social isolation. In addition, lower
xtremity bypass surgery also improved pain, physical mo-
ility, and sleep 1 year after the intervention.47 However,
ecently it was found that quality of life returned to presur-
ery levels in the domains of pain and physical mobility at 1
ear of follow-up.48 These findings suggest that although
ndovascular therapy improves HRQOL acutely, long-
erm outcomes may not be as durable. The NHP is com-
rehensive and has been examined extensively in research
ettings. This questionnaire may be practical for use in
linical settings because it takes only 5 to 10 minutes to
omplete.53,55
World Health Organization Quality of Life Assess-
ent Instrument 100. The World Health Organization
uality of Life Assessment Instrument 100 (WHOQOL-
00) was designed for cross-cultural applicability and thus
as developed in several different languages.56-60 The in-
trument is composed of six domains, including physical
ealth, psychological state, level of independence, social
ionnaires to assess functional status and/or health-
atients within multiple interventions
Interventions Most effective intervention
ovascular therapy; bypass
rgery; unsupervised exercise
Endovascular therapy and
bypass surgery
ovascular and medical therapy;
edical therapy
Endovascular and medical
therapy
ovascular and medical therapy;
edical therapy
No differences between
groups
ovascular therapy; bypass
rgery; medical therapy
Did not distinguish HRQOL
between groups
ervised exercise; unsupervised
ercise; IPC
IPC and supervised exercise
ervised exercise; supervised
ercise and medication;c home-
sed exercise
Inconclusive
ovascular therapy; medical
erapy
Endovascular therapy
ovascular and medical therapy;
edical therapy
Endovascular and medical
therapy
ovascular therapy; supervised
ercise
Supervised exercise
ovascular therapy; supervised
cise;e combined group
Combined group
CQ, Intermittent Claudication Questionnaire; IPC, intermittent pneumatic
Occlusive Disease 86-item questionnaire; SF-36, Short Form 36-item
QOL, Vascular Quality of Life questionnaire; WIQ, Walking Impairment
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May 20111416 Mays et alsonal beliefs, incorporating 24 quality of life “facets” and
100 total items. Responses are determined from 5-point
Likert scales (eg, very dissatisfied  1; very satisfied  5).
Using a reduced version of theWHOQOL-100 (17 facets),
Breek et al60 established that patients with IC had lower
scores in the domains of physical health and level of inde-
pendence as well as many facets compared with healthy
controls. In one of the few studies to use the WHOQOL-
100 to evaluate an intervention (ie, angioplasty, bypass
surgery, endarterectomy, amputation) for patients with IC,
there were improvements in physical health and level of
independence.61 Although the WHOQOL-100 is well es-
tablished in other disease states, more studies are warranted
to determine the effect of treatment on HRQOL for IC.
The original questionnaire is probably too long to be
practical for clinical use, but the reduced version may have
value for use in the clinical setting.57
McMaster Health Index Questionnaire. McMaster
Health Index Questionnaire (MHIQ) is composed of 59
health-related items covering physical, social, and emo-
tional dimensions. The physical function domain consists
of 24 items, including physical activities, mobility, and
self-care activities. There are 25 social function items that
assess general welfare, family, and friend’s support and
participation, and global social function. The 25 emotional
function items include self-esteem, feelings about personal
relationships, thoughts about the future, critical life events,
and global emotional function. Because some of the items
address both social and emotional functions within the
same question, the consolidated number of items is 59. For
each of the three dimensions, scores are based on index
values of 0 to 1, with lower scores indicating worse func-
tion. Compared with other general questionnaires, few
studies have used the MHIQ to assess HRQOL in patients
with IC.62,63 However, findings indicate impairments in
general health and physical, social, and emotional function
when compared with age-matched controls.63 After 24
weeks of pharmacologic therapy, Brevetti et al64 found that
patients randomized to receive propionyl-L-carnitine im-
proved physical and emotional function and the global
scores compared with the group receiving a placebo. There
may be use for this questionnaire in clinical settings.
PAD-SPECIFIC QUESTIONNAIRES
Disease-specific HRQOL questionnaires for PAD were
developed to examine how IC affects the well-being and
ability of patients to function. Although less generalizable
than HRQOL questionnaires developed for use across dis-
ease states, these tools allow for a more in-depth assessment
of specific health issues related to PAD. This is particularly
important because of the debilitating effects of IC on
HRQOL, particularly in the physical domains compared
with the psychosocial domains.65
Walking Impairment Questionnaire. The Walking
Impairment Questionnaire (WIQ) was one of the first
disease-specific questionnaires for assessing functional sta-
tus in PAD patients and remains widely used.66 The WIQ
was validated in several large studies and is available inmany different languages.67-72 In the initial validation as well as
n subsequent studies, the questionnaire results were cor-
elated to treadmill measures of performance (ie, peak
alking distance, peak oxygen consumption, and onset of
laudication pain) in PAD patients.66 The WIQ assesses
ow limited patients are in walking defined distances and
peeds and the degree of difficulty climbing flights of stairs.
ymptoms that limit walking are also assessed. Scoring is on
0% to 100% scale. The WIQ has been used to establish
hat limitations in walking speeds and distances as well as in
tair climbing are present in patients with IC compared
ith controls.4,73 The WIQ has also been shown to detect
mpairment in PAD patients who have mild symptoms or
re asymptomatic.74
The WIQ has been used extensively to evaluate the
fficacy of several types of therapy for IC, including exercise
raining,66,75-79 peripheral bypass surgery,66,80 endovascu-
ar therapy,81,82 andmany types of medications.83-86 In the
nitial development and validation, Regensteiner et al66
ompared WIQ scores of claudication patients before and
fter 12 weeks of supervised treadmill walking and 6 weeks
fter bypass surgery. Both treatments significantly im-
roved the distance and speed domains as well as treadmill
alking, demonstrating the positive impact of both treat-
ents. Matsuo and Shigematsu85 examined changes in
unctional status assessed by the Japanese version of the
IQ for IC patients. Patients were stratified by ankle-
rachial index values and treated for 8 weeks with prosta-
landin E1 in lipid microspheres. The WIQ subscales im-
roved for all groups, demonstrating sensitivity to the
reatment. Thus, the WIQ is a valid, reliable, and sensitive
ool for assessing functional status of PAD patients for
vailable treatment options. This questionnaire is brief and
an be used in the clinical or research settings to provide
nformation about walking impairment.
Claudication Scale. The Claudication Scale (CLAU-S)
as originally developed in Germany and has been trans-
ated into a number of different languages, including
rench, English, Flemish, and Swiss.38,87,88 The different
ersions of this scale are composed of Likert scale items,
ach with a number of domains. The six-domain version
ncludes daily living, pain, complaints, social life, disease-
pecific fears, and mood. Scoring is on a 0 to 100 scale (ie,
 worst score, 100  best score). Most of the studies
sing the CLAU-S in European settings have examined the
ffects of naftidrofuryl (a 5-hydroxytryptamine-2 receptor
ntagonist), a peripheral vasodilator, on IC and have dem-
nstrated mixed results for specific domains, although
alking improvement has been observed. Daily living, pain,
isease-specific fears, and mood improved significantly
ompared with patients who received a placebo.89 How-
ver, D’Hooge et al90 found no changes in disease-specific
ears and mood and an improvement in social life scores
fter naftidrofuryl treatment. Several vascular intervention
tudies have evaluated changes in HRQOL demonstrating
oth short- and long-term improvements in most of the
omains of the CLAU-S.38,91 To the best of our knowl-
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setting to date.
Peripheral Artery Occlusive Disease 86 question-
naire. The Peripheral Artery Occlusive Disease 86 (PAVK-
86) consists of 86 items and seven HRQOL domains that
include functional status, pain, general complaints, mood,
anxiety, social life, and evaluation of treatment. Scoring is
from 1 to 4, with 1 indicating no impairment and 4
indicating high impairment. Holler et al92 examined
PAVK-86 scores spanning PAD severity according to the
Fontaine Classification system (stages II to IV). Patients
experienced greater impairments in pain and functional
status between Fontaine Classification Stage IIb (moderate
to severe claudication) compared with IIa (mild claudica-
tion), indicating that the more advanced disease and sub-
sequent shorter distance to onset of leg pain leads to a
greater impairment of the PAVK-86 physical domains. The
PAVK-86 has been used to evaluate changes in HRQOL
after pharmacologic treatment, supervised and unsuper-
vised exercise training, and combined pharmacologic and
supervised exercise training.93-95 Briefly, all domains except
general complaints improved in patients with IC after 12
weeks of supervised treadmill walking.94 The largest im-
provement was demonstrated in the pain and functional
status domains, indicating that physical domains for IC
patients are generally the most improved by exercise train-
ing. One drawback is that the questionnaire has proven
difficult and lengthy for patients to complete.92
Vascular Quality of Life questionnaire. The Vascu-
lar Quality of Life (VascuQOL) questionnaire was originally
developed for use in patients with Fontaine classification
II-IV (ie, ranging from mild IC to ulceration/gangrene)
and has been translated into multiple languages.96 The
questionnaire contains 25 items subdivided into the do-
mains of pain, symptoms, activities, and social and emo-
tional well-being. Scores are based on responses from a
7-point scale for each item (1 being the lowest score, 7
being highest). Several studies have used it to evaluate the
effect of IC on quality of life.39,97 de Vries et al39 estab-
lished that the instrument discriminated disease severity
among PAD patients. The tool has also been demonstrated
to be sensitive to change in HRQOL after various treat-
ments for IC.27,39,40,98 For instance, Roberts et al98 found
that an unsupervised, home-based exercise program im-
proved all domains of the VascuQOL, except for the social
domain. The original study indicated that the question-
naire was easy for patients to understand and took an
average of 9.6 minutes to complete, indicating it may have
value in clinical settings.96
Peripheral Artery Questionnaire. The Peripheral
Artery Questionnaire (PAQ) is a disease-specific health
status questionnaire for patients with PAD.82,99,100 There
are 20 items scored from worst (0) to best (100) relating to
domains specific to PAD, including (1) identification of the
most symptomatic leg, (2) degree to which PAD limits
normal activities, (3) questions regarding recent improve-
ment or deterioration in symptoms, (4) the frequency and
intensity of claudication, (5) questions regarding patient catisfaction with current treatment, (6) standard quality of
ife and current symptoms and limitations compared with
heir desired level of functioning, and (7) social function.82
n the initial validation study using revascularization, scores
mproved significantly in all PAQ domains. Several current
tudies have examined the validity of the PAQ, including
everal using a Dutch version of the scale.30,101,102 The
uestionnaire is relatively brief and may be useful in the
linical setting.
Sickness Impact Profile–Intermittent Claudication.
he Sickness Impact Profile–Intermittent Claudication
SIPIC), developed from the generic HRQOL 136-item
IP, is a condensed version of the original, containing 12
tems from six domains.103-105 The domains that comprise
he SIPIC are sleep and rest, home management, ambula-
ion, mobility, social interaction and alertness, and behav-
or. Scoring is completed by a positive response to a specific
uestion (eg, 1 point for acknowledgment of walking
horter distances or stopping to rest often). Althoughmany
tudies use the original SIP across various disease states,
elatively few have used the SIPIC version for symptomatic
AD patients after treatment.40,106 Taft et al106 examined
ifferences in HRQOL assessed by the SIPIC in stable IC
fter several different interventions. Patients who received
ndovascular therapy/bypass surgery significantly im-
roved SIPIC scores and also demonstrated larger improve-
ents from baseline than the supervised exercise training
nd control groups. There may be utility in the clinical
etting for this questionnaire because of its brevity.
Intermittent Claudication Questionnaire. The In-
ermittent Claudication Questionnaire (ICQ) consists of
n index of 16 items that focuses on limitations imposed by
laudication while performing various tasks, such as walk-
ng specific distances or performing errands.107 This ques-
ionnaire is a relatively new tool for assessing HRQOL in
AD patients after treatment. Cheetham et al108 demon-
trated that a supervised exercise program improved ICQ
cores by 43% from baseline scores, whereas an advice-only
roup had a nonsignificant improvement of 16% (also used
F-36). Additionally, Kakkos et al109 examined quality of
ife at baseline and after supervised and unsupervised exer-
ise and intermittent pneumatic compression for patients
ith stable IC. Supervised exercise and intermittent pneu-
atic compression both improved ICQ scores at 6 weeks
nd 6 months after baseline. The questionnaire has also
een validated in Turkish.110 Overall, testing for use in
ymptomatic PAD patients has been limited. However, the
CQ may be a practical tool for use in clinical settings
ecause the average time for completing the questionnaire
s 3.7 minutes.107
LINICAL RELEVANCE OF HRQOL AND
UNCTIONAL STATUS ASSESSMENT
The questionnaires discussed in this review have been
ore commonly used in the research setting than the
linical setting. Finding reports about results of question-
aire use in the clinical setting is difficult because often
linicians may not publish results of a questionnaire used
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into clinical practice, there are not direct examples in the
literature of a claudication research trial substantially alter-
ing clinical management as a result of questionnaire use.
However, the role for questionnaires in the clinical setting
should be further explored because patient outcomes pro-
vide important information about treatment efficacy. For
instance, understanding patient goals may help in making
treatment decisions. The treatment options presented to
the patient may not meet their expectations, which may
affect adherence to the treatment and could adversely affect
the patient’s physical, mental, and emotional satisfaction
with care.111 Assessing HRQOL and functional status may
assist in circumventing future problems with treatment
choice and ultimately improve the health of PAD patients
with claudication.
CONCLUSIONS
HRQOL is defined as a patient’s perceived physical,
emotional, and social well-being and function. It has been
estimated that 2 million individuals with IC have a re-
duced quality of life, particularly relating to limitations in
ambulation.10,112 It is important for health care providers
to evaluate the burden of the disease, which ultimately will
guide selection of appropriate treatments for improving the
HRQOL of PAD patients. Thus, questionnaires that are
simple, accurate, and effective for determining perceived
quality of life and functional status in patients with IC have
utility in clinical as well as research settings. Future research
shouldmove toward a consensus on the best questionnaires
available for symptomatic PAD patients and standardize the
implementation and interpretation of these tools in clinical
settings.
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